Clinical Trial

Balanced Multi-Electrolyte Solution Versus Saline Trial for Diabetic KetoAcidosis

Study acronym: BEST-DKA
Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated September 17, 2025 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this blinded, cluster cross-over, randomised controlled trial is to determine whether fluid therapy with Plasma-Lyte® 148 increases the number of days alive and days out of hospital to day-28 compared to 0.9% sodium chloride ('0.9% saline') in critically ill patients presenting to the Emergency Department (ED) and deemed to require admission to a critical care area (ICU, HDU) with moderate to severe diabetic ketoacidosis (DKA).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-02-28; most recent amendment 2025-09-10.
Status change: Not Yet Recruiting → Recruiting 2025-09-10
Trial Details
NCT Number NCT05752279
Lead Sponsor The George Institute
Conditions Diabetic Ketoacidosis
Enrollment 680 participants
Start Date 2024-03-14
Primary Completion 2026-07 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2025-09-17